Stockreport

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome, Inc.  (IMNM) 
PDF Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on d [Read more]